Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Tuberous Sclerosis 1Multiple Endocrine Neoplasia Type 1 1Focal Cortical Dysplasia 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Fulvestrant 5Exercise 5Eating 5Standard of Care 3Sodium Chloride 3Diet 3Alpelisib 3ribociclib 2gallium Ga 68 dotatate 2exemestane 2Vitamin D 2Tamoxifen 2Magnetic Resonance Spectroscopy 2Letrozole 2Ethanol 2Blood Specimen Collection 2Anastrozole 2zopiclone 1ziprasidone 1veliparib 1testosterone undecanoate 1testosterone enanthate 1pazopanib 1mirabegron 1methyl hydroxyethyl cellulose 1lenvatinib 1fluorocholine 1evolocumab 1dimethandrolone-undecanoate 1cyclopropapyrroloindole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Endocrine Neoplasia Type 1 × Carbamazepine × Clear all
NCT05028608 2022-02-25

A Study to Learn What Happens to Elinzanetant in the Body When Taken With or Without Carbamazepine, and How Safe it is in Healthy Men and Women Aged 18 to 60 Years.

Bayer

Phase 1 Completed
16 enrolled
Endocrine

Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡